Cover Image
市場調查報告書

原發性顫抖症:開發中產品分析

Essential Tremor - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 362368
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
原發性顫抖症:開發中產品分析 Essential Tremor - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 49 Pages
簡介

本報告提供原發性顫抖症治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

原發性顫抖症概要

治療藥的開發

  • 開發中產品的概要

原發性顫抖症:企業開發中的治療藥

原發性顫抖症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

原發性顫抖症:企業開發中的產品

原發性顫抖症的治療藥的開發企業

  • Merz GmbH & Co. KGaA
  • Neurocrine Biosciences, Inc.
  • Sage Therapeutics, Inc.

原發性顫抖症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

原發性顫抖症:最近的開發平台趨勢

原發性顫抖症:暫停中的計劃

原發性顫抖症:開發中止的產品

原發性顫抖症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8154IDB

Summary

Global Markets Direct's, 'Essential Tremor - Pipeline Review, H1 2016', provides an overview of the Essential Tremor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Essential Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Essential Tremor
  • The report reviews pipeline therapeutics for Essential Tremor by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Essential Tremor therapeutics and enlists all their major and minor projects
  • The report assesses Essential Tremor therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Essential Tremor

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Essential Tremor
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Essential Tremor pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Essential Tremor Overview
  • Therapeutics Development
    • Pipeline Products for Essential Tremor - Overview
  • Essential Tremor - Therapeutics under Development by Companies
  • Essential Tremor - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Essential Tremor - Products under Development by Companies
  • Essential Tremor - Companies Involved in Therapeutics Development
    • Merz GmbH & Co. KGaA
    • Neurocrine Biosciences, Inc.
    • Sage Therapeutics, Inc.
  • Essential Tremor - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • incobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NBI-640756 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAGE-217 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sepranolone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Essential Tremor - Recent Pipeline Updates
  • Essential Tremor - Dormant Projects
  • Essential Tremor - Discontinued Products
  • Essential Tremor - Product Development Milestones
    • Featured News & Press Releases
      • Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting
      • Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
      • Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor
      • Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Essential Tremor, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Essential Tremor - Pipeline by Merz GmbH & Co. KGaA, H1 2016
  • Essential Tremor - Pipeline by Neurocrine Biosciences, Inc., H1 2016
  • Essential Tremor - Pipeline by Sage Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Essential Tremor Therapeutics - Recent Pipeline Updates, H1 2016
  • Essential Tremor - Dormant Projects, H1 2016
  • Essential Tremor - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Essential Tremor, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top